Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses using dutasteride, both topical and oral, for hair loss in trans men, considering potential side effects like depression and libido issues. The user is exploring options including topical solutions with minoxidil, retinoic acid, and hydrocortisone, and plans to start microneedling.

First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

The conversation discusses concerns about using cordyceps while on dutasteride due to potential DHT increase, with OP experiencing hair loss after using creatine. OP is advised to stop creatine and give dutasteride more time to evaluate its effectiveness.

The conversation is about a user considering reducing their dutasteride dose due to side effects like lower libido and watery semen. They plan to use dutasteride mesotherapy every three months to maintain hair while reducing systemic DHT suppression.

Topical aldactone is discussed for its effects on men's hair and muscles. The conversation explores its potential benefits and side effects compared to other treatments like Minoxidil, finasteride, and RU58841.

A 21-year-old male is experiencing crown balding and is using RU58841, topical minoxidil, and plans to add dutasteride and oral minoxidil to his treatment. He seeks advice on increasing his treatment stack despite previous side effects like chest pain.

The user has been using finasteride for hair loss and is considering adding RU58841. They ask about RU58841's effectiveness, potential heart side effects, duration of action, dosage increase over time, transitioning to GT20029, and where to find the liquid form.

The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

A combination of pyrilutamide, minoxidil, and alfatradiol is proposed as an effective alternative to finasteride for treating mild to moderate hair loss, claiming to stabilize hair loss and improve thickness without finasteride's side effects. Some users are skeptical about the effectiveness and approval of these treatments, while others are interested in trying them due to finasteride's side effects.

The user experienced side effects from a hair loss treatment and is considering using pyrilutamide, alfatradiol, and possibly minoxidil. They are unsure about starting minoxidil immediately or waiting to see the effects of the other treatments.

The user is considering adding an anti-androgen, RU58841, to their current hair loss treatment routine due to receding hair. They are also contemplating waiting for Breezula or Pyrilutamide to become more affordable.

The user started a hair care routine using 0.5mg finasteride daily, 2ml of 5% minoxidil, and 4.5mg of cetirizine topically to address hair loss. They plan to provide updates and are also interested in cetirizine's potential to reduce scalp itching and redness due to its anti-inflammatory properties.

Switching from minoxidil foam to topical solution and considering adding caffeine, melatonin, or cetirizine. Currently using 2.5mg oral minoxidil and 1mg oral finasteride, planning to ask for 0.5mg oral dutasteride and 5mg oral minoxidil.

The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.

A 31-year-old male switched from finasteride to oral dutasteride (0.5mg, 2x a week) and uses liquid minoxidil daily for hair loss. He experienced shedding and regrowth but is considering increasing dutasteride to 3x a week due to concerns about hair density and ongoing issues.

The user experienced significant hair thickening after using oral minoxidil and dutasteride, with no negative side effects, only increased libido and strength. Dutasteride was used after initial minoxidil treatment, leading to noticeable improvements in hair density.

The conversation discusses the use of vasodilators like Minoxidil, L-arginine, and Niacin for hair regrowth, with Minoxidil causing intolerable side effects for the original poster. It also highlights that certain medications, including Lisinopril, antidepressants, and statins, can cause hair loss.

A 30-year-old male is using dutasteride, minoxidil, ketoconazole shampoo, and various supplements for hair loss, reporting no sexual side effects but experiencing tinnitus. He stopped microneedling and tretinoin cream, saw quick results, and experiences low-intensity shedding.

A user shared their experience with Spironolactone for hair loss, noting it stopped hair loss and cleared acne but had side effects like frequent urination and potential kidney damage. They also mentioned Bicalutamide as a potentially more potent DHT blocker with fewer side effects and asked for others' experiences with DHT blockers for women.

The conversation discusses using tretinoin with topical minoxidil for hair regrowth, despite previous non-response to minoxidil and concerns about oral minoxidil's heart risks. The user is also on dutasteride and is considering a hair transplant if other options fail.

The user is considering minoxidil, clascoterone, and fluridil for hair loss, avoiding finasteride and RU58841. They are also contemplating a hair transplant and exploring the resilience of transplanted hair without finasteride.

The user experienced side effects from low-dose topical finasteride and is considering using clascoterone (CB-03-01) despite concerns about its risks and cost. They seek advice on its effectiveness and potential side effects compared to other treatments like alfatradiol and fluridil.

Dutasteride, at 1 mg daily, was used for hair regrowth, with initial shedding and side effects like watery semen and increased libido. The user previously tried finasteride and minoxidil but switched to dutasteride for stronger, sustained results.

Dutasteride can significantly increase libido, more so than finasteride. Users reported higher libido when switching from finasteride to dutasteride.

The user is experiencing severe side effects from finasteride, including sleep issues, depression, and gynecomastia, and is considering stopping the medication. They are exploring other treatments like RU58841 and dutasteride but are hesitant due to potential side effects.

The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.

The conversation is about using topical tazarotene with minoxidil for hair loss treatment. A user suggests using a lower strength than 0.025% for daily application.

Dutasteride may reduce bone mineral density, but there's no increased risk of osteoporosis or fractures compared to finasteride. Users suggest resistance training to counter potential bone effects.